$904.97
0.13% yesterday
NYSE, Sep 18, 10:10 pm CET
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Eli Lilly and Company Stock price

$904.97
-16.84 1.83% 1M
+142.31 18.66% 6M
+322.05 55.25% YTD
+333.69 58.41% 1Y
+673.33 290.68% 3Y
+792.25 702.85% 5Y
+838.38 1,259.02% 10Y
NYSE, Closing price Wed, Sep 18 2024
-1.21 0.13%
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Key metrics

Market capitalization $860.11b
Enterprise Value $885.71b
P/E (TTM) P/E ratio 113.04
EV/FCF (TTM) EV/FCF 3,435.64
EV/Sales (TTM) EV/Sales 22.76
P/S ratio (TTM) P/S ratio 22.10
P/B ratio (TTM) P/B ratio 63.44
Dividend yield 0.50%
Last dividend (FY23) $4.52
Revenue growth (TTM) Revenue growth 31.87%
Revenue (TTM) Revenue $38.92b
EBIT (operating result TTM) EBIT $13.43b
Free Cash Flow (TTM) Free Cash Flow $257.80m
Cash position $3.36b
EPS (TTM) EPS $8.01
P/E forward 58.03
P/S forward 18.74
EV/Sales forward 19.30
Short interest 0.78%
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Eli Lilly and Company forecast:

26x Buy
81%
5x Hold
16%
1x Sell
3%

Analyst Opinions

32 Analysts have issued a Eli Lilly and Company forecast:

Buy
81%
Hold
16%
Sell
3%

Financial data from Eli Lilly and Company

Dec '23
+/-
%
Net Profit 5,240 5,240
16% 16%
15%
Depreciation and Amortization 1,527 1,527
0% 0%
4%
Stock Compensation 629 629
69% 69%
2%
Operating Cash Flow 4,240 4,240
40% 40%
12%
Investments 7,392 7,392
198% 198%
22%
Dividend Paid 4,069 4,069
15% 15%
12%
Free Cash Flow 793 793
85% 85%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Neutral
Business Wire
about 12 hours ago
TOKYO--(BUSINESS WIRE)-- #DrugDiscovery--Axcelead DDP and Lilly Enter into Research and Collaboration Agreement.
Positive
The Motley Fool
one day ago
A huge opportunity in healthcare today is treatment of patients for diabetes and obesity. Another emerging area with limited competition is treating Alzheimer's disease.
Negative
Barrons
4 days ago
Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna in the second quarter.
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 43,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today